The Chemours Company (NYSE:CC) Shares Bought by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC lifted its stake in shares of The Chemours Company (NYSE:CC) by 14.7% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 14,102 shares of the specialty chemicals company’s stock after acquiring an additional 1,803 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Chemours were worth $318,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. New Covenant Trust Company N.A. purchased a new position in Chemours during the 1st quarter worth approximately $29,000. North Star Investment Management Corp. grew its position in shares of Chemours by 1,510.0% during the first quarter. North Star Investment Management Corp. now owns 1,288 shares of the specialty chemicals company’s stock worth $34,000 after acquiring an additional 1,208 shares during the last quarter. Sunbelt Securities Inc. increased its holdings in shares of Chemours by 1,969.7% in the 1st quarter. Sunbelt Securities Inc. now owns 1,366 shares of the specialty chemicals company’s stock valued at $36,000 after acquiring an additional 1,300 shares during the period. Neo Ivy Capital Management purchased a new stake in Chemours in the 4th quarter valued at $40,000. Finally, Headlands Technologies LLC acquired a new stake in Chemours during the 1st quarter worth $42,000. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Stock Down 0.4 %

CC opened at $20.72 on Friday. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.89 and a quick ratio of 1.01. The Chemours Company has a 12 month low of $15.10 and a 12 month high of $32.70. The stock has a market capitalization of $3.09 billion, a P/E ratio of -9.55 and a beta of 1.74. The business has a 50 day simple moving average of $19.57 and a 200-day simple moving average of $23.68.

Chemours (NYSE:CC) last released its earnings results on Thursday, August 1st. The specialty chemicals company reported $0.38 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.19). Chemours had a net margin of 2.16% and a return on equity of 33.21%. The business had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.53 billion. During the same period last year, the business posted $1.10 EPS. Chemours’s revenue was down 6.4% compared to the same quarter last year. On average, equities analysts anticipate that The Chemours Company will post 1.33 earnings per share for the current fiscal year.

Chemours Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 13th. Investors of record on Thursday, August 15th were issued a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 4.83%. The ex-dividend date of this dividend was Thursday, August 15th. Chemours’s dividend payout ratio is currently -46.08%.

Analyst Ratings Changes

A number of research analysts have commented on CC shares. UBS Group dropped their price objective on shares of Chemours from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Barclays reduced their price objective on Chemours from $22.00 to $21.00 and set an “equal weight” rating for the company in a research note on Wednesday. BMO Capital Markets lowered their target price on Chemours from $35.00 to $30.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Mizuho assumed coverage on Chemours in a report on Friday, June 7th. They issued a “neutral” rating and a $25.00 target price on the stock. Finally, JPMorgan Chase & Co. decreased their price target on Chemours from $25.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, August 6th. Six investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $26.63.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.